A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2025-08-17
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 200
- Registration Number
- NCT05453903
- Locations
- 🇺🇸
The University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Conditions
- Newly Diagnosed Acute Myeloid Leukemia (AML)
- Interventions
- Drug: SKLB1028 Dose Escalation
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 58
- Registration Number
- NCT05445154
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, China
CART-38 in Adult AML and MM Patients
- Conditions
- Acute Myeloid Leukemia (AML)Multiple Myeloma (MM)
- Interventions
- Drug: 3x10(6) CART-38 celllsDrug: 7x10(5) CART-38 cellsDrug: 7x10(6) CART-38 cellsDrug: 3x10(7) CART-38 cells
- First Posted Date
- 2022-07-05
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 11
- Registration Number
- NCT05442580
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
- Conditions
- Acute Myeloid Leukemia
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2025-08-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 270
- Registration Number
- NCT05424562
- Locations
- 🇨🇦
Tom Baker Cancer Centre /ID# 248113, Calgary, Alberta, Canada
🇨🇦University of Alberta Hospital /ID# 251531, Edmonton, Alberta, Canada
🇨🇦BC Cancer - Surrey /ID# 257515, Surrey, British Columbia, Canada
AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission
- Conditions
- Acute Myeloid Leukemia (AML) in Remission
- Interventions
- First Posted Date
- 2022-06-03
- Last Posted Date
- 2022-08-19
- Lead Sponsor
- The First Affiliated Hospital of Soochow University
- Target Recruit Count
- 124
- Registration Number
- NCT05404906
- Locations
- 🇨🇳
First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
🇨🇳The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, Jiangsu, China
A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia
- Conditions
- Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 1
- Registration Number
- NCT05345938
- Locations
- 🇨🇳
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Study of Liposomal Annamycin in Combination with Cytarabine for the Treatment of Subjects with Acute Myeloid Leukemia (AML)
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Moleculin Biotech, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT05319587
- Locations
- 🇮🇹
Istituto Scientifico Romagolo per lo studio dei umori "Dino Amadori" (IRST) - IRCCS, Meldola, FC, Italy
🇮🇹IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
🇮🇹Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Greece
- Conditions
- Acute Myeloid Leukemia
- First Posted Date
- 2022-04-07
- Last Posted Date
- 2025-07-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 100
- Registration Number
- NCT05317494
- Locations
- 🇬🇷
Olympion General Clinic /ID# 268392, Patras, Achaia, Greece
🇬🇷General Hospital of Athens Gennimatas /ID# 245968, Athens, Attiki, Greece
🇬🇷General Hospital of Athens Laiko /ID# 244338, Athens, Attiki, Greece
Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia (AML)Acute Lymphoblastic Leukemia (ALL)
- Interventions
- First Posted Date
- 2022-03-22
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Armaceutica, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT05291390
- Locations
- 🇸🇳
Dalal Jamm Hospital, Guediawaye GOL SUD, Dakar, Senegal
A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Conditions
- Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2022-02-15
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Tarapeutics Science Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT05241106
- Locations
- 🇨🇳
the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China